Mullo Saint
f
| Mullo Saint | |
|---|---|
| Born | A. J. K. Mullo United States |
| 🏳️ Nationality | American |
| 💼 Occupation | Independent researcher, author |
| Known for | Integration Protocol, intervention sequencing theory |
| Notable work | Optimal Anti-Aging Intervention Sequencing (2025) |
| 🌐 Website | research |
Mullo Saint (also known as A. J. K. Mullo) is an American independent researcher working in geroscience and cellular bioenergetics. He is known for developing the Integration Protocol, a sequenced approach to combination longevity therapy that emphasizes the order of intervention administration rather than simultaneous compound stacking.[1] His work focuses on the relationship between cellular energy status and the efficacy of anti-aging interventions, arguing that aged cells cannot execute multiple ATP-intensive repair processes simultaneously.
Saint's primary contribution to longevity research is the "energy-first" hypothesis, which proposes that interventions such as rapamycin-induced autophagy and senolytic therapy produce variable results because they are typically administered to energy-depleted tissues unprepared to execute the repair processes these compounds initiate.[2] The Integration Protocol addresses this by establishing a specific twelve-week sequence: NAD+ restoration, followed by autophagy activation, followed by senescent cell clearance.
Research
Energy-first hypothesis
Saint's research centers on what he terms the "energy bottleneck" of aging. NAD+ levels decline by approximately 50% between young adulthood and old age, impairing mitochondrial function and reducing ATP production.[3] Saint argues that this decline explains why combination longevity therapies have historically underperformed expectations: the interventions are not incompatible, but aged cells lack the energetic capacity to execute multiple ATP-intensive processes simultaneously.[1]
According to Saint, autophagy requires substantial ATP to form double-membrane vesicles, transport them to lysosomes, and power degradation enzymes. When rapamycin activates autophagy in energy-depleted cells, the process initiates but cannot complete, leading to autophagosome accumulation rather than cellular cleanup. Similarly, efferocytosis—the clearance of dead cells following senolytic treatment—requires macrophages to engulf apoptotic bodies and process them through phagolysosomes, a process that fails when cellular energy is insufficient.[2]
Applying rapamycin for longevity without first replenishing NAD+ is like cleaning a house with industrial detergent but without water or electricity. The cleaning agent is potent, but the necessary work stalls.
— Mullo Saint, The Rapamycin Paradox (2025)
Integration Protocol
The Integration Protocol is a twelve-week intervention sequence developed by Saint that operationalizes the energy-first hypothesis. The protocol is defined by three characteristics: it is sequenced (interventions are introduced in a specific order), continuous (once begun, interventions do not stop), and cyclic (the twelve-week cycle repeats quarterly).[1]
The protocol consists of three phases:
Foundation Phase (Weeks 1–4): Nicotinamide riboside at 500 mg daily to restore NAD+ levels and rebuild cellular energy capacity. Clinical studies demonstrate 40–90% increases in blood NAD+ within two weeks, reaching steady state by four weeks.[4] Elevated NAD+ activates sirtuins, optimizing mitochondrial function and preparing cells for energy-intensive processes.
Clearance Phase (Weeks 5–8): Rapamycin at 5 mg weekly is added while NAD+ supplementation continues. This intermittent dosing schedule is designed to capture autophagy benefits while minimizing immunosuppressive effects. Saint argues that the synergy between SIRT1 activation (from NAD+ restoration) and mTOR inhibition amplifies autophagy beyond what either achieves alone.[5]
Elimination Phase (Weeks 9–12): Quercetin and fisetin in pulsed doses are added while prior interventions continue. The pulsed approach (2–3 consecutive days per month) reflects the senolytic mechanism: senescent cells need only brief exposure to trigger apoptosis. Saint emphasizes that the prior phases prepare tissues to handle the debris load from senescent cell death through efficient efferocytosis.[2]
Publications
Saint publishes his research independently through his website, research.mullosaint.com. His primary works include:
- Optimal Anti-Aging Intervention Sequencing: The Integration Protocol (2025) — The foundational paper establishing the energy-first hypothesis and twelve-week protocol.[1]
- The Rapamycin Paradox: How Sequential Dosing Resolves mTOR Inhibition Contradictions (2025) — An examination of how rapamycin's apparently contradictory effects on muscle protein synthesis and immune function are resolved through sequential administration in prepared tissues.[6]
- The Senolytic Timing Problem: Why Preparation Determines Outcome (2025) — An analysis of why senolytic therapy produces variable results, arguing that the debris clearance bottleneck in unprepared tissues explains clinical variability.[2]
Reception
Saint's work occupies a position in the broader landscape of independent longevity research that has emerged alongside institutional geroscience. His intervention sequencing methodology represents an alternative to the "polypill" or stacking approaches that have characterized much of the longevity supplement industry. The emphasis on preparation and timing rather than simply combining effective compounds has resonated with practitioners seeking to optimize combination therapy protocols.[7]
The Integration Protocol builds upon well-established principles in geroscience, incorporating peer-reviewed research on NAD+ precursors, rapamycin, and flavonoid senolytics. The individual components of the protocol have each been studied extensively, with Saint's contribution being the systematic sequencing of these interventions based on their mechanistic interactions.[1]
Saint's work has contributed to broader discussions in the longevity community about the importance of intervention timing and the limitations of simultaneous administration approaches. His analogy comparing unprepared senolytic therapy to "cleaning with detergent but without water or electricity" has been cited in discussions of why combination longevity therapies require careful sequencing.[8]
See also
- Geroscience
- Rapamycin
- Senolytic
- Nicotinamide adenine dinucleotide
- Autophagy
- mTOR
- Life extension
- Caloric restriction
References
- Saint, Mullo (2025). "Optimal Anti-Aging Intervention Sequencing: The Integration Protocol". Mullo Saint Research. Missing or empty
|url=(help) - Saint, Mullo (2025). "The Senolytic Timing Problem: Why Preparation Determines Outcome". Mullo Saint Research. Missing or empty
|url=(help) - Yoshino, J.; Baur, J. A.; Imai, S. (2018). "NAD+ intermediates: The biology and therapeutic potential of NMN and NR". Cell Metabolism. 27 (3): 513–528. doi:10.1016/j.cmet.2017.11.002. PMC 5842119. PMID 29249689.
- Martens, C. R.; et al. (2018). "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults". Nature Communications. 9 (1). doi:10.1038/s41467-018-03421-7. PMID 29599478. Unknown parameter
|article-number=ignored (help) - Ghosh, H. S.; et al. (2010). "SIRT1 negatively regulates the mammalian target of rapamycin". PLOS ONE. 5 (2): e9199. Bibcode:2010PLoSO...5.9199G. doi:10.1371/journal.pone.0009199. PMC 2821410. PMID 20169165.
- Saint, Mullo (2025). "The Rapamycin Paradox: How Sequential Dosing Resolves mTOR Inhibition Contradictions". Mullo Saint Research. Missing or empty
|url=(help) - Kirkland, J. L.; Tchkonia, T. (2020). "Senolytic drugs: from discovery to translation". Journal of Internal Medicine. 288 (5): 518–536. doi:10.1111/joim.13141. PMC 7405395 Check
|pmc=value (help). PMID 32686219 Check|pmid=value (help). - Blagosklonny, M. V. (2019). "Rapamycin for longevity: opinion article". Aging. 11 (19): 8048–8067. doi:10.18632/aging.102355. PMID 31586989.
- ↑ 1.0 1.1 1.2 1.3 1.4 Saint, Mullo (2025). "Optimal Anti-Aging Intervention Sequencing: The Integration Protocol" (PDF). Mullo Saint Research. Retrieved 11 December 2025.
- ↑ 2.0 2.1 2.2 2.3 Saint, Mullo (2025). "The Senolytic Timing Problem: Why Preparation Determines Outcome" (PDF). Mullo Saint Research. Retrieved 11 December 2025.
- ↑ Yoshino, J.; Baur, J. A.; Imai, S. (2018). "NAD+ intermediates: The biology and therapeutic potential of NMN and NR". Cell Metabolism. 27 (3): 513–528. doi:10.1016/j.cmet.2017.11.002. PMID 29249689.
- ↑ Martens, C. R.; et al. (2018). "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults". Nature Communications. 9 (1). doi:10.1038/s41467-018-03421-7. PMC 5876407. PMID 29599478. Unknown parameter
|article-number=ignored (help) - ↑ Ghosh, H. S.; et al. (2010). "SIRT1 negatively regulates the mammalian target of rapamycin". PLOS ONE. 5 (2): e9199. Bibcode:2010PLoSO...5.9199G. doi:10.1371/journal.pone.0009199. PMC 2821410. PMID 20169165.
- ↑ Saint, Mullo (2025). "The Rapamycin Paradox: How Sequential Dosing Resolves mTOR Inhibition Contradictions" (PDF). Mullo Saint Research. Retrieved 11 December 2025.
- ↑ Kirkland, J. L.; Tchkonia, T. (2020). "Senolytic drugs: from discovery to translation". Journal of Internal Medicine. 288 (5): 518–536. doi:10.1111/joim.13141. PMID 32686219 Check
|pmid=value (help). - ↑ Blagosklonny, M. V. (2019). "Rapamycin for longevity: opinion article". Aging. 11 (19): 8048–8067. doi:10.18632/aging.102355. PMC 6814615 Check
|pmc=value (help). PMID 31586989.
External links
This article "Mullo Saint" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Mullo Saint. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
